Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Alterations in GPCR signalling are implicated in the pathogenesis and treatment of neuropsychiatric55, immunological56, gastrointestinal57,58, cardiac59, renal, hormonal, infectious60 and many other disorders53,54.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [55]
In the citing paper
“most clinically effective antipsychotics also exhibit a myriad of other actions that contribute to both therapeutic and side-effect profiles [359,360].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [360]
In the citing paper
“This often generates beneficial therapeutic activities,102 due to additive or synergistic pharmacological effects.103”
From QSAR without borders (2020) · cites this paper as [102]
Citations
Cites
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
(2003) · The Lancet · doi:10.1016/s0140-6736(03)12705-5 · Cited by 1,706
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,349
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Genome Scan Meta-Analysis of Schizophrenia and Bipolar Disorder, Part II: Schizophrenia
Lewis, C. M., Levinson, D. F., Wise, L. H., DeLisi, L. E., Straub, R. E., Hovatta, I., Williams, N. M., Schwab, S. G., Pulver, A. E., Faraone, S. V., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/376549 · Cited by 1,137
The Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia
Meltzer, H. Y., & McGurk, S. R. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033376 · Cited by 1,020
Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 968
Self-citationBurris, K. D., Molski, T. F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033175 · Cited by 922
Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
Thase, M. E., Entsuah, A. R., & Rudolph, R. L. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.3.234 · Cited by 801
Kroeze, W. K., Hufeisen, S. J., Popadak, B. A., Renock, S. M., Steinberg, S., Ernsberger, P., Jayathilake, K., Meltzer, H. Y., & Roth, B. L. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300027 · Cited by 801
Self-citationLeucht, S., Wahlbeck, K., Hamann, J., & Kissling, W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13306-5 · Cited by 725
Rothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., & Roth, B. L. (2000) · Circulation · doi:10.1161/01.cir.102.23.2836 · Cited by 722
Self-citationKane, J. M., Carson, W. H., Saha, A. R., McQuade, R. D., Ingenito, G. G., Zimbroff, D. L., & Ali, M. W. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0903 · Cited by 624
Genes for schizophrenia? Recent findings and their pathophysiological implications
Harrison, P. J., & Owen, M. J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12379-3 · Cited by 597
Lawler, C. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00099-2 · Cited by 408
Castner, S. A., Williams, G. V., & Goldman-Rakic, P. S. (2000) · Science · doi:10.1126/science.287.5460.2020 · Cited by 401
G-protein-coupled receptors at a glance
Kroeze, W. K., Sheffler, D. J., & Roth, B. L. (2003) · Journal of Cell Science · doi:10.1242/jcs.00902 · Cited by 380
Self-citationFinding the Intracellular Signaling Pathways Affected by Mood Disorder Treatments
Coyle, J. T., & Duman, R. S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00195-8 · Cited by 360
Meta-analytical studies on new antidepressants
Anderson, I. M. (2001) · British Medical Bulletin · doi:10.1093/bmb/57.1.161 · Cited by 351
Meltzer, H. Y., Arvanitis, L., Bauer, D., Rein, W., & Meta-Trial Study Group (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.975 · Cited by 330
The Physiological Role of 5-HT2AReceptors in Working Memory
Williams, G. V., Rao, S. G., & Goldman-Rakic, P. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-07-02843.2002 · Cited by 311
Pérez, V., Gilaberte, I., Faries, D., Alvarez, E., & Artigas, F. (1997) · The Lancet · doi:10.1016/s0140-6736(96)08007-5 · Cited by 300
Kikuchi, T., Tottori, K., Uwahodo, Y., Hirose, T., Miwa, T., Oshiro, Y., & Morita, S. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10600-9 · Cited by 276
Efficacy at g-protein-coupled receptors
Kenakin, T. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd722 · Cited by 263
Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate
Fontaine, K. R., Heo, M., Harrigan, E. P., Shear, C. L., Lakshminarayanan, M., Casey, D. E., & Allison, D. B. (2001) · Psychiatry Research · doi:10.1016/s0165-1781(01)00234-7 · Cited by 230
Suessbrich, H., Waldegger, S., Lang, F., & Busch, A. E. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00355-9 · Cited by 222
A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze
Woolley, M. L., Bentley, J. C., Sleight, A. J., Marsden, C. A., & Fone, K. C. F. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00056-9 · Cited by 206
Kramer, M. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830180085011 · Cited by 199
Zubenko, G. S., Maher, B., Hughes, H. B., Zubenko, W. N., Stiffler, J. S., Kaplan, B. B., & Marazita, M. L. (2003) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20073 · Cited by 191
Anthony Altar, C., Wasley, A. M., Neale, R. F., & Stone, G. A. (1986) · Brain Research Bulletin · doi:10.1016/0361-9230(86)90181-4 · Cited by 176
A historical perspective of clozapine.
Hippius, H. (1999) · PubMed · Cited by 166
Multiple mechanisms of serotonergic signal transduction
Roth, B. L., & Chuang, D. M. (1987) · Life Sciences · doi:10.1016/0024-3205(87)90621-7 · Cited by 158
Self-citationComparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression
Stahl, S. M., Entsuah, R., & Rudolph, R. L. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01425-7 · Cited by 151
Schizophrenia and L-745, 870, a novel dopamine D4 receptor antagonist
Bristow, L. J., Kramer, M. S., Kulagowski, J. J., Patel, S. S., RAGAN, C. I., & Seabrook, G. R. (1997) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)01066-3 · Cited by 132
d-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia
Evins, A. E., Amico, E. T., Posever, T. A., Toker, R., & GOFF, D. C. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00220-1 · Cited by 120
Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients
van Berckel, B. N. M., Hijman, R., van der Linden, J. A., Westenberg, H. G. M., van Ree, J. M., & Kahn, R. S. (1996) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00311-3 · Cited by 109
Lahti, A. C., Weiler, M. A., Corey, P. K., Lahti, R. A., Carlsson, A., & Tamminga, C. A. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00030-9 · Cited by 104
Tuunainen, A., Wahlbeck, K., & Gilbody, S. M. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00212-2 · Cited by 103
Placebo-Controlled Study of the D4/5-HT2A Antagonist Fananserin in the Treatment of Schizophrenia
Truffinet, P., Tamminga, C. A., Fabre, L. F., Meltzer, H. Y., Rivi�re, M.-E., & Papillon-Downey, C. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.3.419 · Cited by 94
Inoue, T., Domae, M., Yamada, K., & Furukawa, T. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12799-7 · Cited by 92
Atypical antipsychotic drug actions: unitary or multiple mechanisms for ‘atypicality’?
Roth, B. L., Sheffler, D. J., & Potkin, S. G. (2003) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(03)00021-5 · Cited by 92
Self-citationDiscovering risperidone: the LSD model of psychopathology
Colpaert, F. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1062 · Cited by 78
Berman, R., Anand, A., Cappiello, A., Miller, H., Hu, X. S., Oren, D. A., & Charney, D. S. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00383-7 · Cited by 78
de Paulis, T. (2001) · PubMed · Cited by 71
BMY 14802, a Sigma Receptor Ligand for the Treatment of Schizophrenia
Gewirtz, G. R., Gorman, J. M., Volavka, J., Macaluso, J., Gribkoff, G., Taylor, D. P., & Borison, R. L. (1994) · Neuropsychopharmacology · doi:10.1038/npp.1994.5 · Cited by 63
In need of high-throughput behavioral systems
Brunner, D., Nestler, E. J., & Leahy, E. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(02)02423-6 · Cited by 61
Dopamine agonists in schizophrenia: a review
Benkert, O., Muller-Siecheneder, F., & Wetzel, H. (1995) · European Neuropsychopharmacology · doi:10.1016/0924-977x(95)00022-h · Cited by 60
Schizophrenia and L-745, 870, a novel dopamine D4 receptor antagonist
Bristow, L. J., Kramer, M. S., Kulagowski, J. J., et al. (1997) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)90618-0 · Cited by 48
New hope in the treatment of painful symptoms in depression.
Briley, M. (2003) · PubMed · Cited by 41
Rasmussen, T., Fink‐Jensen, A., Sauerberg, P., Swedberg, M. D. B., Thomsen, C., Sheardown, M. J., Jeppesen, L., Calligaro, D. O., DeLapp, N. W., Whitesitt, C. A., et al. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00129-8 · Cited by 38
Effects of the D 3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia
Lahti, A. C., Weiler, M. A., Carlsson, A., & Tamminga, C. A. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050091 · Cited by 38
Setola, V., & Roth, B. L. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.6.1277 · Cited by 35
Self-citationA note on the discovery of selective serotonin reuptake inhibitors
Carlsson, A., & Wong, D. T. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)00662-0 · Cited by 28
Amsterdam, J. D., Brunswick, D. J., & Hundert, M. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00298-1 · Cited by 26
Bohannon, J. (2002) · Science · doi:10.1126/science.298.5602.2320 · Cited by 25
Is 3-PPP a potential antipsychotic agent? Evidence from animal behavioural studies
Clark, D. T., Carlsson, A., Hjorth, S., Svensson, K. A., Engel, J. A., & Sanchez, D. (1982) · European Journal of Pharmacology · doi:10.1016/0014-2999(82)90297-7 · Cited by 23
Novel Directions in Antipsychotic Target Identification using Gene Arrays
Palfreyman, M. G., Hook, D. J., Klimczak, L. J., Brockman, J. A., Evans, D., & Altar, C. A. (2002) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007024606203 · Cited by 20
Müller, M. J., Gründer, G., Wetzel, H., Muller-Siecheneder, F., Marx-Dannigkeit, P., & Benkert, O. (1999) · Psychiatry Research · doi:10.1016/s0165-1781(99)00100-6 · Cited by 19
Fischer, G., & Wagner, B. (1983) · PubMed · Cited by 19
Feighner, J. P., Ehrensing, R. H., Kastin, A. J., Patel, A., Sverdlov, L., Hlavka, J., Abajian, H. B., Noble, J. F., & Nicolau, G. (2001) · International Clinical Psychopharmacology · doi:10.1097/00004850-200111000-00005 · Cited by 18
Remington, G. J., & Kapur, S. (2001) · PubMed · Cited by 16
Looking backwards: a possible new path for drug discovery in psychopharmacology
Shorter, E. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd964 · Cited by 15
Research works printed but not linked: 1
- Hemrick–Luecke, S. et al. Pharmacological activity of aripiprazole at presynaptic and postsynaptic dopamine receptors and in antipsychotic models. Proc. Soc. Neurosci. 894.9 (2002).
Cited by
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
The physiology, signaling, and pharmacology of dopamine receptors
Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763
Relating protein pharmacology by ligand chemistry
Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., & Shoichet, B. K. (2007) · Nature Biotechnology · doi:10.1038/nbt1284 · Cited by 2,402
Self-citationTargeted drug delivery to tumors: Myths, reality and possibility
Bae, Y. H., & Park, K. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.001 · Cited by 1,935
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
Metadata
- Authors
- Roth, B. L., Sheffler, D. J., & Kroeze, W. K.
- Affiliations
- Case Western Reserve University (US)
- Corresponding author
- Roth, Bryan L.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-04
- Volume
- 3
- Issue
- 4
- Pages
- 353-359
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2122995608
- Cited by
- 1,155
- References
- 63
- Citations by year
- 2026: 29 · 2025: 28 · 2024: 37 · 2023: 39 · 2022: 47 · 2021: 49 · 2020: 49 · 2019: 63 · 2018: 46 · 2017: 42 · 2016: 61 · 2015: 65 · 2014: 58 · 2013: 73 · 2012: 83
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- magic bullet, polygenic disease, mood disorders, schizophrenia, depression, bipolar disorder, central nervous system disorders, drug target selectivity, polypharmacology, antipsychotic drug development
- MeSH terms
- Humans, Schizophrenia, Antipsychotic Agents, Drugs, Investigational, Comorbidity, Mood Disorders, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.